Key Takeaways
- India branded business the weak spot: Only 5% YoY growth dragged overall performance; management calls the fix a matter of months, not years, and is reworking field execution without adding headcount.
- US generics delivering despite pricing pressure: 13% YoY growth on volume gains and four new launches, with Entresto now launched and 10–15 more products coming this year. Management expects at least 10% growth each remaining quarter.
- Gross margin improved 140 bps to 76.2%: Product mix and manufacturing cost programs drove the gain, aided by low raw material costs this quarter.
- API business in a structural squeeze: Chinese traders leaking Indian export pricing data has eroded pricing power for 6–7 quarters; management expects a tough couple of quarters before slow growth resumes.
- What to watch next quarter: Whether India branded business growth accelerates toward double digits, the pace and margin profile of the 4–5 planned Q2 US launches, and any tariff-related channel behavior in the US.
India Branded Business: The Core Problem
- Execution, not demand: The 5% YoY growth reflects internal execution issues, not market weakness. Management cited the challenge of moving 7,000+ salespeople to new processes, stricter alignment to UCPMP norms, and a newly implemented secondary-sales capture mechanism that gives better inventory visibility but requires adjustment.
- Benchmarked to compliant peers: The company studied the top 2–3 UCPMP-compliant firms that delivered strong growth and is reworking its operations to match those benchmarks. The focus is better execution in every district and headquarters, not adding headcount.
- Specialty areas lagging: Some momentum exists in specialty segments but not enough to pull the overall branded business into robust double-digit growth. Animal Healthcare, by contrast, continues to perform well on strong execution.
- Turnaround confidence is high but unquantified: Management says the timeframe is months, not years, to reach double-digit growth and match or beat market growth, but declined to give an exact date.
Shaunak Amin: "I can't give you exact timeframe, but like I said, it's a matter of months that we start seeing double-digit growth and beating or matching market growth."
US Generics: Volume Offsetting Price Erosion
- Growth driven by launches and account wins: The 13% YoY growth came from four new product launches plus picking up accounts on older products where market uncertainty existed, at pricing that worked for the company.
- Entresto launched with in-house API: The product has generic competition and price erosion because it was an innovative product, but it remains a decent market. Alembic has in-house API, which helps margin.
- Pipeline is the growth engine: 2 ANDAs filed this quarter, 6 approvals received, and 10–15 more products expected to launch in the rest of FY26. Management expects at least 10% growth in each of Q2, Q3 and Q4, implying full-year US growth of 10–15%.
- Complex injectables progressing slowly: One approval received (Doxorubicin, already public), with a few more expected gradually. The company is also pursuing Tirzepatide for a potential day-1 US launch and other peptide-based complex injectables.
- Tariff stance is pragmatic, not panicked: Management has seen no channel stocking or destocking related to tariffs. On high-volume, wafer-thin margin products, tariffs would make the business unviable, and the company would walk away from some business if necessary rather than supply at a loss. US manufacturing purely for tariff de-risking is not being considered; it would only make sense with a US government business strategy or better pricing opportunity.
Pranav Amin: "Increasing manufacturing footprint in the US just because of tariffs is something, in my opinion, not something that we are considering. If there was a strategy based on US government business or something that you can get at a better pricing, then we would look at a manufacturing strategy in the US. But purely for the de-risk perspective, it doesn't make sense to allocate so much capital for setting a manufacturing in the US."
API Business: A Structural Pricing Problem
- Six-to-seven-quarter erosion driven by data leaks: Chinese traders now leak data on Indian export prices, revealing what price each supplier is selling at and to which buyer. This has destroyed the pricing advantage Alembic historically enjoyed from its strong compliance record, causing account losses and margin pressure.
- Not a demand problem: The inherent business strength as a supply chain and development partner remains intact. Management expects a tough couple of quarters, then slow growth to resume.
- API tariff risk is existential: Management views potential API tariffs as catastrophic, though they do not currently believe such tariffs will materialize.
Pranav Amin: "Now with this data that is getting leaked through Chinese traders, everyone knows what price you're selling it at, to which buyer. And that's really caused a lot of appeal and a lot of uncertainty in terms of our pricing."
Margins & Cost Structure
- Gross margin improved on mix and cost programs: Gross margin rose from 74.8% to 76.2%, driven by product mix and manufacturing cost improvement programs. Low raw material costs this quarter also helped.
- EBITDA before R&D grew ~23% YoY: Revenue growth, better gross margins, and improved utilization in some facilities launched last year all contributed.
- R&D spend rising as guided: R&D expenses up 26% YoY to ₹145 crores, in line with the full-year guidance of ₹600–₹650 crores.
- Depreciation stepped up: The company commissioned a new manufacturing facility for blended business in Q1, establishing a new depreciation base. Further capitalization from the ₹400 crore CAPEX program will add more depreciation as projects are completed.
- Raw material cost range: Expected to stay in the 25–30% of revenue range going forward, varying with product mix between API and generics.
- Operating leverage still to come: New manufacturing facilities (injectable, Derm, Onco, and the new OSD facility) are at lower utilization levels. As they ramp up, management expects improved operating leverage to help margins. Formulation plant F1 and API plants are already running at practical peak capacity.
International & RoW Generics
- Strong quarter, partly base-effect aided: Rest of world generics grew 21%, driven by strategic expansion and execution across geographies. Q1 last year was muted, making this quarter look higher.
- Full-year expectation: Management expects RoW to grow close to 10–15% for the full year.
- Semaglutide opportunity is second-wave: The company was late for the first wave of Semaglutide launches in the US and will not participate. RoW markets are being evaluated, but management declined to name specific countries until regulatory strategy and filings are in place.
- Tirzepatide and other peptides in development: Tirzepatide (Mounjaro) is being pursued for a potential day-1 US launch. Other peptide-based complex injectables are also in the pipeline.
Balance Sheet & Capital Allocation
- Working capital broadly stable: Better collections were partially offset by an increase in inventory, in line with the company's strategic approach to working capital.
- CAPEX is maintenance-heavy: The ₹400 crore full-year CAPEX is mainly for maintenance, replacement and debottlenecking, with very little toward expansion or upgrades. Most capacity augmentation projects are already completed.
- Debt trajectory uncertain: Management declined to commit to a substantial reduction in net debt this year, saying working capital needs will drive the outcome and that the topic will be discussed next quarter.
- Full-year ETR: Expected in the range of 17–18%.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| US business growth | At least 10% growth each quarter; full-year 10–15% | Q2–Q4 FY26 |
| US product launches | 4–5 more products in Q2; 10–15 in the rest of FY26 | Q2 and full-year FY26 |
| India branded business | Return to double-digit growth, beating or matching market growth | Within months (no exact date) |
| RoW generics growth | Close to 10–15% growth | Full-year FY26 |
| R&D spend | ₹600–₹650 crores | Full-year FY26 |
| CAPEX | ~₹400 crores, mainly maintenance and debottlenecking | Full-year FY26 |
| Full-year ETR | 17–18% | Full-year FY26 |
| API business recovery | Slow growth to resume after a tough couple of quarters | 2–3 quarters out |
Key Metrics
| Metric | Q1 FY26 |
|---|---|
| Total revenue | ₹1,711 cr, +10% YoY |
| India branded business revenue | ₹599 cr, +5% YoY |
| US generics revenue growth | +13% YoY, supported by volume gains |
| Rest of world generics revenue growth | +21% YoY |
| API business revenue | ₹261 cr, flat YoY |
| Gross margin (net of material cost) | 76.2%, improved from 74.8% in Q1 FY25 |
| EBITDA margin before R&D | 25% of revenue, ₹424 cr, +23% YoY |
| EBITDA after R&D | ₹288 cr, 17% of revenue, +20% YoY |
| R&D expenses | ₹145 cr, +26% YoY; full-year guidance ₹600–650 cr |
| Profit before tax | ₹191 cr, +21% YoY |
| Net profit | ₹154 cr, +15% YoY |
| EPS | ₹7.85 per share, vs ₹6.84 in Q1 FY25 |
| Gross debt | ₹1,185 cr as of June 30 |
| Net debt | ₹967 cr as of June 30 |
| US business as share of total | ~29% of total business |
| ANDAs filed in quarter | 2 filed; 6 approvals received; 4 products launched |
| US launches expected in Q2 FY26 | 4 to 5 products |
| US full-year growth expectation | 10% to 15% |
| RoW full-year growth expectation | close to about 10%–15% at least |
| Effective tax rate | ~19% in Q1; full-year guidance 17%–18% |
| CAPEX guidance for FY26 | ~₹400 cr, primarily maintenance, replacement, debottlenecking |